Sangamo Therapeutics (SGMOQ) Assets Average (2011 - 2025)

Sangamo Therapeutics' Assets Average history runs 15 years deep, the most recent figure standing at $74.2 million for Q4 2025.

• On a quarterly basis, Assets Average fell 30.3% year-over-year to $74.2 million in Q4 2025; TTM through Dec 2025 was $74.2 million, a 30.3% decrease from a year earlier, with the FY2025 full-year figure at $80.7 million, down 39.55% from the prior year.
• Assets Average retreated to $74.2 million in Q4 2025 per SGMOQ's latest filing, from $93.1 million in the prior quarter.
• Across five years, Assets Average topped out at $907.8 million in Q1 2021 and bottomed at $74.2 million in Q4 2025.
• The 5-year median for Assets Average is $327.6 million (2023), against an average of $399.6 million.
• Across the five-year window, Assets Average surged 48.61% in 2021 and plunged 71.01% in 2024, its largest moves.
• Year by year, Assets Average stood at $747.2 million in 2021, then fell by 22.61% to $578.2 million in 2022, then plunged by 66.71% to $192.5 million in 2023, then tumbled by 44.7% to $106.4 million in 2024, then sank by 30.3% to $74.2 million in 2025.
• Per Business Quant, the three latest SGMOQ Assets Average figures stand at $74.2 million (Q4 2025), $93.1 million (Q3 2025), and $91.9 million (Q2 2025).